Incidence of ethambutol-related visual impairment during treatment of active tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 4, 2013, Pages 447-455

  Ezer, N ^a   Benedetti, A ^a   Darvish Zargar, M ^b   Menzies, D ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Blindness; Eye toxicity; Meta analysis; Systematic review; Tuberculosis treatment

Indexed keywords

ETHAMBUTOL;

ADULT; AGE DISTRIBUTION; DATA ANALYSIS; DATA BASE; DOSE RESPONSE; DRUG INDUCED DISEASE; EYE TOXICITY; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; SHORT COURSE THERAPY; SNELLEN CHART; SYSTEMATIC REVIEW; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOSIS CONTROL; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; ETHAMBUTOL; HUMANS; INCIDENCE; MIDDLE AGED; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TUBERCULOSIS; VISION DISORDERS; VISION TESTS; VISION, OCULAR; YOUNG ADULT;

EID: 84875447392     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0766     Document Type: Review

References (34)

1. Enarson D A, Rieder H L, Arnadottir T, Trébucq A. Tuberculosis guide for low-income countries. 5th ed. Paris, France: International Union Against Tuberculosis and Lung Disease, 200-0.
2. World Health Organization. Treatment of tuberculosis guidelines. 4th ed. WHO/HTM/TB/2009.420. Geneva, Switzerland: WHO, 200-9.
3. Lönnroth K, Raviglione M. Global epidemiology of tuberculosis: prospects for control. Semin Respir Crit Care Med 2008; 29: 481-49-1.
4. Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLOS Med 2009; 6: e100014-6.
5. Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLOS Med 2009; 6: e100015-0.
6. Lew W, Oxlade O, Pai M, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 2008; 149: 123-13-4.
7. World Health Organization. Global tuberculosis control: WHO report 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 201-1.
8. Pion S D, Kamgno J, Demanga-Ngangue B M. Excess mortality associated with blindness in the onchocerciasis focus of the Mbam Valley, Cameroon. Ann Trop Med Parasitol 2002; 96: 181-18-9.
9. Frick K D, Foster A. The magnitude and cost of global blindness: an increasing problem that can be alleviated. Am J Ophthalmol 2003; 135: 471-47-6.
10. Hamza T H, Houwelingen H C, Stijnen T. The binomial distribution of meta-analysis was preferred to model within-study variability. J Clin Epidemiol 2008; 61: 41-5-1.
11. Zamora J, Abraira V, Muriel A, Khan K S, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006; 6: 3-1.
12. Tsai R K, Lee Y H. Reversibility of ethambutol optic neurotherapy. J Ocul Pharmacol Ther 1997; 13: 473-47-7.
13. Woung L C, Jou J R, Liaw S L. Visual function in recovered ethambutol optic neuropathy. J Ocul Pharmacol Ther 1995; 11: 411-41-9.
14. Chuenkongkaew W, Samsen P, Thanasombatskul N. Ethambutol and optic neuropathy. J Med Assoc Thai 2003; 86: 62-5.
15. Bobrowitz I D, Gokulanathan K S. Ethambutol in the retreatment of pulmonary tuberculosis. Dis Chest 1965; 48: 239-25-0.
16. Bobrowitz I D. Comparison of ethambutol-INH versus INHPAS in original treatment of pulmonary tuberculosis. Ann N Y Acad Sci 1966; 135: 921-93-9.
17. Leibold J E. The ocular toxicity of ethambutol and its relation to dose. Ann N Y Acad Sci 1966; 135: 904-90-9.
18. National Sanatoria in Japan. Clinical efficacy of new antituberculosis drugs, ethionamide, cycloserine and dextro-2-2′-(ethylenediimino)-DI-1- butanol (ethambutol, ebutol) in retreatment: eighth series of controlled trials: Part 2. Tubercle 1966; 47: 361-36-9.
19. Donomae I, Yamamoto K. Clinical evaluation of ethambutol in pulmonary tuberculosis. Ann N Y Acad Sci 1966; 135: 849-88-1.
20. Tacquet A, Devulder B. [Ethambutol in the treatment of pulmonary tuberculosis]. Rev Tuberc Pneumol (Paris) 1968; 32: 729-748. [French]
21. Tiburtius H. The undesired side-effects of myambutol. Antibiot Chemother 1970; 16: 298-30-1.
22. Radenbach K L. Results of clinical studies with capreomycin, ethambutol and rifampicin in the Heckeshorn Hospital, Berlin. Scand J Respir Dis Suppl 1969; 69: 43-5-3.
23. Lees A W, Allan G W, et al. Toxicity from rifampicin plus isoniazid and rifampicin plus ethambutol therapy. Tubercle 1971; 52: 182-19-0.
24. Aquinas M, Citron K M. Rifampicin, ethambutol and capreomycin in pulmonary tuberculosis, previously treated with both first and second line drugs: the results of 2 years chemotherapy. Tubercle 1972; 53: 153-16-5.
25. Clarke M, Cuthbert J, Cuthbert R J, Lees A W. Isoniazid plus ethambutol in the initial treatment of pulmonary tuberculosis. Brit J Dis Chest 1972; 66: 272-27-5.
26. British Medical Research Council Hong Kong. A controlled clinical trial of daily and intermittent regimens of rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis in Hong Kong. Tubercle 1974; 55: 1-2-7.
27. Lee E J, Kim S J, Choung H K, Kim J H, Yu Y S. Incidence and clinical features of ethambutol-induced eptic neuropathy in Korea. J Neuroophthalmol 2008; 28: 269-27-7.
28. Jindani A, Nunn A J, Enarson D A. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364: 1244-125-1.
29. Menon V, Jain D, Saxena R, Sood R. Prospective evaluation of visual function for early detection of ethambutol toxicity. Br J Ophthalmol 2009; 93: 1251-125-4.
30. Steininger W J. Ethambutol in the retreatment of pulmonary tuberculosis. United States Public Health Service cooperative trial. Bull Int Union Tuberc 1968; 41: 181-18-2.
31. Delacoux E, Moreau Y, Godefroy A, Evstingneeff Th. Prévention de la toxicité oculaire de l'éthambutol: intérêt de la zincémie et de l'analyse du sens chromatique. J Fr Ophtalmol 1978; 1: 191-196. [French]
32. Tuberculosis Research Centre India. Ethambutol plus isoniazid for the treatment of pulmonary tuberculosis: a controlled trial of four regimens. Tubercle 1981; 62: 13-2-9.
33. De Palma P, Franco F, Bragliani G, et al. The incidence of optic neuropathy in 84 patients treated with ethambutol. Metab Pediatr Syst Ophthalmol 1989; 12: 80-8-2.
34. Griffith D E, Brown-Elliott B A, Shepherd S, McLarty J, Griffith L, Wallace R J Jr. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2005; 172: 250-25-3.